Email
IZ Express #1,675: Register for February 28 webinar on improving the vaccination experience, and more
| From | Immunize.org <[email protected]> |
| Subject | IZ Express #1,675: Register for February 28 webinar on improving the vaccination experience, and more |
| Date | February 1, 2023 11:02 AM |
Links have been removed from this email. Learn more in the FAQ.
Links have been removed from this email. Learn more in the FAQ.
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,675: February 1, 2023
Top Stories
* “Improving the Vaccination Experience: Reducing Pain and Anxiety for Children and Adults”; join Immunize.org February 28 for our webinar
* “Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages among Immunocompetent Adults—Increasing Community Access to Testing Program, United States, December 2022–January 2023” published in MMWR Early Release
* “Information for Persons Who Are Immunocompromised regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages—United States, January 2023” published in MMWR Early Release
* “Laboratory-Confirmed COVID-19 Case Incidence Rates among Residents in Nursing Homes by Up-to-Date Vaccination Status—United States, October 10, 2022–January 8, 2023” published in MMWR
* Influenza is still active in some areas; keep vaccinating
* CDC revises parts of its General Best Practice Guidelines for Immunization
* Spotlight: Immunize.org resources grouped by age cohorts
* Vaccines in the news
Immunize.org Pages and Handouts
* Immunize.org updates three standing orders templates for adult vaccination—Td/Tdap, Tdap during pregnancy, and meningococcal ACWY
* Immunize.org updates handout titled “Leading Medical Organizations Endorse Strong School and Childcare Vaccination Requirements and Elimination of Non-medical Exemptions”
* Immunize.org updates its patient handout “Rabies: Questions and Answers”
* Recap: See updated Immunize.org clinician materials released in December and January
Vaccine Information Statements
* Immunize.org continues to expand its translations of new and updated Rabies and Polio Vaccine Information Statements. Be sure to use the latest translations!
* Recap: Use new Vaccine Information Statements and translations released in December and January
Featured Resources
* Updated 65+ Flu Defense website offers resources for healthcare professionals caring for older adults
* Explore the www.Give2MenACWY.org website to increase coverage with the MenACWY booster and other adolescent vaccinations
Notable Publications
* “SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents after Receipt of Bivalent COVID-19 Vaccine—Ohio and Rhode Island, September–November 2022” published in MMWR
* “Persistent COVID-19 Symptoms at 6 Months after Onset and the Role of Vaccination before or after SARS-CoV-2 Infection” published in Infectious Diseases
Upcoming Events
* Virtual: Watch February 22–24 ACIP meeting; agenda is now available
------------------------------------------------------------
Top Stories
------------------------------------------------------------
“Improving the Vaccination Experience: Reducing Pain and Anxiety for Children and Adults”; join Immunize.org February 28 for our webinar
Anxiety about needles and injections affects as many as 2 out of 3 children and 1 out of 4 adults. This anxiety can contribute to dreading, delaying, or avoiding vaccinations, even when the importance of preventing illness is understood. Good news: there are safe, effective, and practical steps that vaccinators, vaccine recipients, and caregivers can take to reduce vaccination-related pain and anxiety. Creating a less stressful vaccination experience increases confidence in vaccination.
Attend this live, 1-hour webinar hosted by Immunize.org, Improving the Vaccination Experience: Reducing Pain and Anxiety for Children and Adults ([link removed]) at 1:00 p.m. (ET) on February 28 to learn more about the principles behind vaccination pain and anxiety. Learn simple evidence-based strategies to reduce apprehension. These strategies were developed by the experts from HELP Eliminate Pain in Kids and Adults ([link removed]). Their work was used by the World Health Organization (WHO), Public Health Canada, and others to develop guidelines for reducing vaccination pain.
The panelists will be:
* Anna Taddio, BScPhm, PhD; Professor, Faculty of Pharmacy, University of Toronto; Senior Associate Scientist, The Hospital for Sick Children (SickKids), Toronto, Ontario
* Kelly L. Moore, MD, MPH; President and CEO, Immunize.org
* Lucie Marisa Bucci, MA; Director, Policy and Government Relations, Society for Infodemic Management (SIM), Québec, Québec
* Sharon Humiston, MD, MPH; Director for Research, Immunize.org
Following the presentation, ample time is reserved for your questions.
Register now ([link removed]) to be sure you don’t miss this important session to help you make vaccination a more positive experience for everyone.
------------------------------------------------------------
“Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages among Immunocompetent Adults—Increasing Community Access to Testing Program, United States, December 2022–January 2023” published in MMWR Early Release
CDC published Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages among Immunocompetent Adults—Increasing Community Access to Testing Program, United States, December 2022–January 2023 ([link removed]) in the January 25 issue of MMWR Early Release. A portion of the summary appears below.
Using spike (S)-gene target presence as a proxy for BA.2 sublineages, including XBB and XBB.1.5, during December 2022–January 2023, the results showed that a bivalent mRNA booster dose provided additional protection against symptomatic XBB/XBB.1.5 infection for at least the first 3 months after vaccination in persons who had previously received 2–4 monovalent vaccine doses.
Access the MMWR article in HTML ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Information for Persons Who Are Immunocompromised regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages—United States, January 2023” published in MMWR Early Release
CDC published Information for Persons Who Are Immunocompromised regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages—United States, January 2023 ([link removed]) in the January 27 issue of MMWR Early Release. A portion of the article appears below.
As of January 20, 2023, >90% of circulating SARS-CoV-2 variants in the United States, specifically Omicron BQ.1, BQ.1.1, XBB, and XBB.1.5 sublineages, are unlikely to be susceptible to the combined monoclonal antibodies, tixagevimab and cilgavimab (Evusheld) used for preexposure prophylaxis against SARS-CoV-2 infection (1). The Food and Drug Administration announced on January 26, 2023, that Evusheld is not currently authorized for preexposure prophylaxis against SARS-CoV-2 infection in the United States. It is important that persons who are moderately to severely immunocompromised, those who might have an inadequate immune response to COVID-19 vaccination, and those with contraindications to receipt of COVID-19 vaccines, exercise caution and recognize the need for additional preventive measures. . . . In addition, persons should have a care plan that includes prompt testing at the onset of COVID-19 symptoms and rapid access to antivirals if SARS-CoV-2 infection is detected.
Access the MMWR article in HTML ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Laboratory-Confirmed COVID-19 Case Incidence Rates among Residents in Nursing Homes by Up-to-Date Vaccination Status—United States, October 10, 2022–January 8, 2023” published in MMWR
CDC published Laboratory-Confirmed COVID-19 Case Incidence Rates among Residents in Nursing Homes by Up-to-Date Vaccination Status—United States, October 10, 2022–January 8, 2023 ([link removed]) in the January 27 issue of MMWR ([link removed]). A portion of the summary appears below.
Nursing home residents who were not up to date with recommended COVID-19 vaccines had a 30%–50% higher risk for acquiring SARS-CoV-2 infection compared with residents who were up to date with COVID-19 vaccines.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
Influenza is still active in some areas; keep vaccinating
Keep encouraging influenza vaccination of those not yet protected. Although this influenza season peaked early, it is not possible to rule out a late season resurgence. CDC’s Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), provides a valuable snapshot of influenza activity state by state.
Influenza Surveillance
For week 3, ending January 21, CDC's Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), reports that nationwide, 2.6% of outpatient visits were due to respiratory illness that included fever plus a cough or sore throat (i.e., influenza-like illness [ILI]). This is just above the national baseline of 2.5%. Multiple respiratory viruses are co-circulating; the relative contribution of influenza virus infection to ILI varies by location. So far this season, 91 children have died from influenza-associated causes.
Influenza Vaccination Dashboard
CDC's Weekly Flu Vaccination Dashboard ([link removed]) shows that vaccination coverage for all children age 6 months to age 17 years is similar to the estimate at the same time in January 2022 (50.1% compared with 49.6%) and 3.2 percentage points lower compared with same time in January 2021 (50.1% compared with 53.3%).
CDC recommends everyone age 6 months and older get annual influenza vaccination. “Vaccines.gov” offers VaccineFinder ([link removed]), a service of Boston Children’s Hospital, to help people find influenza and COVID-19 vaccines for any age group. To be listed as a provider by VaccineFinder, see the information at this website ([link removed]).
Related Links
* CDC: Weekly National Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: Influenza (Flu) ([link removed]) main page
* Immunize.org: free educational materials and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
* Families Fighting Flu: Flu Resources for Healthcare Professionals ([link removed]) main page
------------------------------------------------------------
CDC revises parts of its General Best Practice Guidelines for Immunization
On January 21, CDC updated the list of errata/updates ([link removed]) for its General Best Practice Guidelines for Immunization ([link removed]). Recent updates include:
Timing and Spacing of Immunobiologics – Unknown or Uncertain Vaccination Status
Page 32, Table 3-2: Fifteen-valent and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) were added with an explanatory footnote.
Vaccine Administration
Pages 101, Table 6-1: PCV15 and PCV20 were added.
Storage and Handling of Immunobiologics
Page 120, Table 7-1: PCV15 and PCV20 were added.
Altered Immunocompetence
Page 133: Clarification was added to guidance involving recombinant zoster vaccine (RZV) re-administration to recipients of hematopoietic stem cell transplants. More specificity on the timing of vaccination was added, relative to antiviral timing.
Related Link
* CDC: General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) ([link removed]) (PDF, 198 pages)
Back to top (#Top)
------------------------------------------------------------
Spotlight: Immunize.org resources grouped by age cohorts
In this week's Spotlight, we summarize resources at Immunize.org that focus on specific vaccine products.
Our CDC Schedules ([link removed]) main page provides printable PDFs of the recommended immunization schedules for children and adolescents and for adults.
Our Schedules for Patients ([link removed]) main page contains links to informational sheets on vaccines recommended for people with varying needs based on their age and/or underlying medical conditions.
Within our Handouts: Topic Index ([link removed]) we feature:
* Adult Vaccination ([link removed])
* Adolescent Vaccination ([link removed])
* Parent Handouts ([link removed])
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Washington Post: FDA Advisers Favor Retiring Original COVID Shot and Using Newer Version ([link removed]) (1/26/23)
* STAT: Live Blog: Tracking the Meeting of the FDA Advisory Panel on COVID Vaccines ([link removed]) (1/26/23)
* U.S. News & World Report: To Sway the Unvaccinated, Latino Teens Deputized as Health Educators ([link removed]) (1/24/23)
* Healio: Children Bore Brunt of ‘Early and Intense’ Flu Season ([link removed]) (1/23/23)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Immunize.org updates three standing orders templates for adult vaccination—Td/Tdap, Tdap during pregnancy, and meningococcal ACWY
Immunize.org revised three standing orders templates for adult vaccination with added information on the use of the anterolateral thigh muscle as an alternate site for IM injection in adults and QR codes linking to the online versions of the documents. Links and additional changes are shown below.
* Standing Orders for Administering Td/Tdap Vaccine to Adults ([link removed])
* Standing Orders for Administering Tdap Vaccine during Pregnancy ([link removed]): Replaced "pregnant women" with "during pregnancy" in the title
* Standing Orders for Administering Meningococcal ACWY Vaccine to Adults ([link removed]): Added information regarding timing and spacing of additional MenACWY vaccine doses for immunocompromised patients
Related Links
* Immunize.org: Standing Orders Templates for Administering Vaccines ([link removed]) main page
* Immunize.org: Vaccines: Tetanus ([link removed]) main page
* Immunize.org: Vaccines: Diphtheria ([link removed]) main page
* Immunize.org: Vaccines: Pertussis ([link removed]) main page
* Immunize.org: Vaccines: Meningococcal ACWY ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Immunize.org updates handout titled “Leading Medical Organizations Endorse Strong School and Childcare Vaccination Requirements and Elimination of Non-medical Exemptions”
Immunize.org updated its handout titled Leading Medical Organizations Endorse Strong School and Childcare Vaccination Requirements and Elimination of Non-medical Exemptions ([link removed]). This one-page handout for policymakers lists organizations' policies that endorse:
* Childcare and school vaccination requirements
* Elimination of personal belief and religious exemptions
Changes include updated and reaffirmed policy statements from many of the listed medical organizations and the Society for Healthcare Epidemiology of America's policy adopted in 2021. The handout now has a QR code linking to the online version of the document.
Related Links
* Immunize.org: State Laws and Mandates by Vaccine ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Immunize.org updates its patient handout “Rabies: Questions and Answers”
Immunize.org updated its patient handout Rabies: Questions and Answers ([link removed]), organizing questions and answers into sub-categories, incorporating more complete information on pre-exposure prophylaxis, and adding a QR code to link to the online version of the document.
Related Links
* Immunize.org: Handouts: Rabies ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Recap: See updated Immunize.org clinician materials released in December and January
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials for healthcare professionals and handouts for patients. All Immunize.org materials are free to distribute.
In case you missed them during recent weeks, updates were made to these helpful materials:
Immunize.org Materials for Clinicians
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) (1/05/23)
* Screening Checklist for Contraindications to Vaccines for Adults ([link removed])
* Vaccines with Diluents: How to Use Them ([link removed])
* Administering Vaccines: Dose, Route, Site, and Needle Size ([link removed])
* Administering Vaccines to Adults: Dose, Route, Site, and Needle Size ([link removed])
* How to Administer Intramuscular and Subcutaneous Vaccine Injections ([link removed])
* How to Administer Intramuscular and Subcutaneous Vaccine Injections to Adults ([link removed])
Immunize.org Web Pages
* Ask the Experts: COVID-19 ([link removed])
* Ask the Experts: Administering Vaccines ([link removed])
* Vaccines: Mpox ([link removed])
Immunize.org Printable Materials for Patients
* After the Shots . . . What to Do if Your Child Has Discomfort ([link removed])
* Reliable Sources of Immunization Information: Where Parents Can Go to Find Answers! ([link removed])
* Protect Yourself from Hepatitis A and Hepatitis B: A Guide for Gay and Bisexual Men ([link removed])
Related Links
* Immunize.org: Handouts ([link removed]) main page to see educational materials sorted by category
* Immunize.org: Ask the Experts ([link removed]) main page to access more than 1,200 questions answered by Immunize.org experts
* Immunize.org: Clinic Tools ([link removed]) main page and its nine subtopics
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical list of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Immunize.org continues to expand its translations of new and updated Rabies and Polio Vaccine Information Statements. Be sure to use the latest translations!
Thanks to CDC support, Immunize.org substantially expanded its repository of Vaccination Information Statement (VIS) ([link removed]) translations. Immunize.org posted new and updated VIS translations for HPV, rotavirus, Td, and Tdap vaccines.
All translations are available in print-ready PDF format.
Rabies VIS (view in English ([link removed]))
New! Armenian ([link removed])
New! Dari ([link removed])
New! German ([link removed])
New! Hindi ([link removed])
New! Italian ([link removed])
New! Japanese ([link removed])
New! Khmer (Cambodian) ([link removed])
New! Korean ([link removed])
New! Polish ([link removed])
New! Swahili (Kiswahili) ([link removed])
New! Tagalog ([link removed])
New! Urdu ([link removed])
New! Yiddish ([link removed])
Polio VIS (view in English ([link removed]))
Updated: Armenian ([link removed])
Updated: Farsi ([link removed])
New! German ([link removed])
Updated: Hindi ([link removed])
New! Italian ([link removed])
Updated: Japanese ([link removed])
Updated: Khmer (Cambodian) ([link removed])
Updated: Korean ([link removed])
New! Polish ([link removed])
New! Swahili (Kiswahili) ([link removed])
Updated: Tagalog ([link removed])
New! Urdu ([link removed])
New! Yiddish ([link removed])
Check the version dates of your office copies of newly updated translations. Translations of previous VIS versions should be discarded now that translations of the current versions are available.
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages ([link removed])
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Recap: Use new Vaccine Information Statements and translations released in December and January
In November, with support from CDC, Immunize.org began working with partners to significantly increase the number of Vaccine Information Statement (VIS) translations available. If your facility works with patients whose primary language is not English, please use these translations.
* 29 translations of the Rabies VIS ([link removed])
* 28 translations of the Smallpox/Monkeypox VIS ([link removed])
* 15 translations each of:
+ HPV (Human Papillomavirus) VIS ([link removed])
+ MMRV (Measles, Mumps, Rubella, Varicella) VIS ([link removed])
+ Rotavirus VIS ([link removed])
+ Tdap (Tetanus, Diphtheria, Pertussis) VIS ([link removed])
+ Varicella (Chickenpox) VIS ([link removed])
* 13 translations each of:
+ DTaP (Diphtheria, Tetanus, Pertussis) VIS ([link removed])
+ Hepatitis A VIS ([link removed])
+ Hepatitis B VIS ([link removed])
+ Haemophilus influenzae (Hib) VIS ([link removed])
+ Meningococcal ACWY VIS ([link removed])
+ Meningococcal B VIS ([link removed])
+ Polio VIS ([link removed])
+ Recombinant Zoster (Shingles) VIS ([link removed])
* 6 translations each of:
+ Influenza (Inactivated or Recombinant) VIS ([link removed])
+ Influenza (Live, Intranasal) VIS ([link removed])
+ MMR (Measles, Mumps, Rubella) VIS ([link removed])
+ Td (Tetanus, Diphtheria) VIS ([link removed])
* Dengue VIS ([link removed]) and Ebola VIS ([link removed]) were each translated into Turkish
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Updated 65+ Flu Defense website offers resources for healthcare professionals caring for older adults
Confident recommendations for influenza vaccine from healthcare providers are powerfully persuasive. To assist you in maximizing protection for your patients, Immunize.org, in collaboration with CSL Seqirus, updated the 65+ Flu Defense ([link removed]) website.
Older adults are at increased risk of severe influenza and COVID-19 illness, including hospitalization and death, especially if they are not up to date on these vaccinations. An updated fact sheet on The Importance of Preventing Influenza and COVID-19, ([link removed]) ([link removed]) offers responses to help guide discussions with patients on the importance of preventing influenza and COVID-19.
This helpful site includes information, tools, and tips for communicating with adults age 65 and older about the scope and severity of influenza. Resources include:
* Influenza in Adults 65+: The Facts ([link removed])
* Influenza Vaccination: Questions Patients Aged 65 and Older Frequently Ask Their HCP ([link removed])
* The Importance of Preventing Influenza and COVID-19 ([link removed])
Check out the updated 65+ Flu Defense website at www.influenza-defense.org ([link removed]) to assist your ongoing efforts in protecting this vulnerable population.
------------------------------------------------------------
Explore the www.Give2MenACWY.org website to increase coverage with the MenACWY booster and other adolescent vaccinations
Immunize.org's www.Give2MenACWY.org ([link removed]) website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines because of the pandemic, so vaccination is more important than ever.
Materials on this colorful website for healthcare professionals incorporate the 2020 ACIP meningococcal vaccine recommendations ([link removed]) and coverage statistics from CDC’s National Immunization Survey–Teen (NIS–Teen). One particularly popular resource on the site is the updated Algorithm for MenACWY Immunization in Adolescents 11 through 18 Years of Age ([link removed]).
The website is divided into five easy-to-access sections:
* Vaccinate Teens ([link removed]) – Teen vaccination schedules and tips for improving vaccination rates
* Give 2 Doses ([link removed]) – Tools to help improve second dose coverage of MenACWY vaccine
* 16-Year-Old Visit ([link removed]) – Resources to help providers and patients remember the important vaccines recommended for 16-year-olds
* Tools for Providers ([link removed]) – Tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
* Resources ([link removed]) – Links to print materials ([link removed]), organizations ([link removed]) involved in adolescent vaccination, personal stories ([link removed]) about the importance of vaccination, and other resources ([link removed]) of interest
The site also categorizes materials ([link removed]) according to whether they are primarily of interest to providers, to adolescents, or to parents.
Visit Give2MenACWY.org ([link removed]) and enjoy browsing (and deploying) its bountiful resources.
Related Links
* Give2MenACWY.org ([link removed]) website
* Algorithm for MenACWY Immunization in Adolescents 11–18 Years of Age ([link removed])
* MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection ([link removed])
* Recommending MenACWY: What to Say and How to Say It ([link removed])
* Top 10 Ways to Improve Adolescent Immunization Rates ([link removed])
* Developing an Immunization Culture in Your Office ([link removed])
* Know Your Rates: Measuring Immunization Success in Your Practice ([link removed])
* You're 16: We Recommend These Vaccines for You ([link removed])
* Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations ([link removed]) – signed by six medical societies
* Ask the Experts: Meningococcal ACWY ([link removed])
* CDC: 2020 ACIP Meningococcal Vaccine Recommendations ([link removed])
* CDC: National, Regional, State, and Selected Local Area Vaccination Coverage among Adolescents Aged 13–17 Years — United States, 2020 ([link removed])
* CDC: Adolescent Vaccination Coverage in the U.S. ([link removed])
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents after Receipt of Bivalent COVID-19 Vaccine—Ohio and Rhode Island, September–November 2022” published in MMWR
CDC published SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents after Receipt of Bivalent COVID-19 Vaccine—Ohio and Rhode Island, September–November 2022 ([link removed]) on January 27 in MMWR ([link removed]). A portion of the summary appears below.
Among nursing home residents in two states, SARS-CoV-2 antibody levels waned within months after vaccination, irrespective of previous SARS-CoV-2 infection, after monovalent booster vaccination. Antibody response broadened after the COVID-19 bivalent booster for vaccinated nursing home residents among those with and without previous infection.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Persistent COVID-19 Symptoms at 6 Months after Onset and the Role of Vaccination before or after SARS-CoV-2 Infection” published in Infectious Diseases
In the January 18 issue, Infectious Diseases published Persistent COVID-19 Symptoms at 6 Months after Onset and the Role of Vaccination before or after SARS-CoV-2 Infection ([link removed]). The Conclusions and Relevance and the Meaning sections appear below.
In this cohort study, more severe acute illness, a higher Charlson Comorbidity Index score, and being unvaccinated were associated with a higher risk of reporting COVID-19 symptoms lasting 28 days or more. Participants with COVID-19 were more likely to seek medical care for diabetes, pulmonary, neurological, and mental health–related illness for at least 6 months after onset compared with their pre-COVID baseline health care use patterns. . . .
The findings suggest that COVID-19 is associated with increased health care encounters through 6 months after infection; vaccination was associated with lower risk of long-term COVID-19 symptoms.
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Watch February 22–24 ACIP meeting; agenda is now available
Event: CDC will convene its Advisory Committee on Immunization Practices ([link removed]) (ACIP).
When:
* February 22 and 23, 8:00 a.m.–5:30 p.m. (ET)
* February 24, 8:00 a.m.–1:10 p.m. (ET)
Agenda ([link removed]): mpox, rotavirus, influenza, pneumococcal, meningococcal, polio, respiratory syncytial virus (pediatric/maternal and adult), chikungunya, dengue, varicella, and COVID-19 vaccines
Registration: Not needed. Opportunities for public comment are described at the website.
Related Links
* ACIP main page ([link removed]) for access to webcast, agendas
* ACIP: Meeting Information ([link removed]) for presentation slides, content from previous meetings, and information about future meetings
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles. When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
[link removed]
[link removed]
[link removed] [link removed]
Email not displaying correctly? View it in your browser ([link removed]).
[link removed]
Issue 1,675: February 1, 2023
Top Stories
* “Improving the Vaccination Experience: Reducing Pain and Anxiety for Children and Adults”; join Immunize.org February 28 for our webinar
* “Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages among Immunocompetent Adults—Increasing Community Access to Testing Program, United States, December 2022–January 2023” published in MMWR Early Release
* “Information for Persons Who Are Immunocompromised regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages—United States, January 2023” published in MMWR Early Release
* “Laboratory-Confirmed COVID-19 Case Incidence Rates among Residents in Nursing Homes by Up-to-Date Vaccination Status—United States, October 10, 2022–January 8, 2023” published in MMWR
* Influenza is still active in some areas; keep vaccinating
* CDC revises parts of its General Best Practice Guidelines for Immunization
* Spotlight: Immunize.org resources grouped by age cohorts
* Vaccines in the news
Immunize.org Pages and Handouts
* Immunize.org updates three standing orders templates for adult vaccination—Td/Tdap, Tdap during pregnancy, and meningococcal ACWY
* Immunize.org updates handout titled “Leading Medical Organizations Endorse Strong School and Childcare Vaccination Requirements and Elimination of Non-medical Exemptions”
* Immunize.org updates its patient handout “Rabies: Questions and Answers”
* Recap: See updated Immunize.org clinician materials released in December and January
Vaccine Information Statements
* Immunize.org continues to expand its translations of new and updated Rabies and Polio Vaccine Information Statements. Be sure to use the latest translations!
* Recap: Use new Vaccine Information Statements and translations released in December and January
Featured Resources
* Updated 65+ Flu Defense website offers resources for healthcare professionals caring for older adults
* Explore the www.Give2MenACWY.org website to increase coverage with the MenACWY booster and other adolescent vaccinations
Notable Publications
* “SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents after Receipt of Bivalent COVID-19 Vaccine—Ohio and Rhode Island, September–November 2022” published in MMWR
* “Persistent COVID-19 Symptoms at 6 Months after Onset and the Role of Vaccination before or after SARS-CoV-2 Infection” published in Infectious Diseases
Upcoming Events
* Virtual: Watch February 22–24 ACIP meeting; agenda is now available
------------------------------------------------------------
Top Stories
------------------------------------------------------------
“Improving the Vaccination Experience: Reducing Pain and Anxiety for Children and Adults”; join Immunize.org February 28 for our webinar
Anxiety about needles and injections affects as many as 2 out of 3 children and 1 out of 4 adults. This anxiety can contribute to dreading, delaying, or avoiding vaccinations, even when the importance of preventing illness is understood. Good news: there are safe, effective, and practical steps that vaccinators, vaccine recipients, and caregivers can take to reduce vaccination-related pain and anxiety. Creating a less stressful vaccination experience increases confidence in vaccination.
Attend this live, 1-hour webinar hosted by Immunize.org, Improving the Vaccination Experience: Reducing Pain and Anxiety for Children and Adults ([link removed]) at 1:00 p.m. (ET) on February 28 to learn more about the principles behind vaccination pain and anxiety. Learn simple evidence-based strategies to reduce apprehension. These strategies were developed by the experts from HELP Eliminate Pain in Kids and Adults ([link removed]). Their work was used by the World Health Organization (WHO), Public Health Canada, and others to develop guidelines for reducing vaccination pain.
The panelists will be:
* Anna Taddio, BScPhm, PhD; Professor, Faculty of Pharmacy, University of Toronto; Senior Associate Scientist, The Hospital for Sick Children (SickKids), Toronto, Ontario
* Kelly L. Moore, MD, MPH; President and CEO, Immunize.org
* Lucie Marisa Bucci, MA; Director, Policy and Government Relations, Society for Infodemic Management (SIM), Québec, Québec
* Sharon Humiston, MD, MPH; Director for Research, Immunize.org
Following the presentation, ample time is reserved for your questions.
Register now ([link removed]) to be sure you don’t miss this important session to help you make vaccination a more positive experience for everyone.
------------------------------------------------------------
“Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages among Immunocompetent Adults—Increasing Community Access to Testing Program, United States, December 2022–January 2023” published in MMWR Early Release
CDC published Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages among Immunocompetent Adults—Increasing Community Access to Testing Program, United States, December 2022–January 2023 ([link removed]) in the January 25 issue of MMWR Early Release. A portion of the summary appears below.
Using spike (S)-gene target presence as a proxy for BA.2 sublineages, including XBB and XBB.1.5, during December 2022–January 2023, the results showed that a bivalent mRNA booster dose provided additional protection against symptomatic XBB/XBB.1.5 infection for at least the first 3 months after vaccination in persons who had previously received 2–4 monovalent vaccine doses.
Access the MMWR article in HTML ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Information for Persons Who Are Immunocompromised regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages—United States, January 2023” published in MMWR Early Release
CDC published Information for Persons Who Are Immunocompromised regarding Prevention and Treatment of SARS-CoV-2 Infection in the Context of Currently Circulating Omicron Sublineages—United States, January 2023 ([link removed]) in the January 27 issue of MMWR Early Release. A portion of the article appears below.
As of January 20, 2023, >90% of circulating SARS-CoV-2 variants in the United States, specifically Omicron BQ.1, BQ.1.1, XBB, and XBB.1.5 sublineages, are unlikely to be susceptible to the combined monoclonal antibodies, tixagevimab and cilgavimab (Evusheld) used for preexposure prophylaxis against SARS-CoV-2 infection (1). The Food and Drug Administration announced on January 26, 2023, that Evusheld is not currently authorized for preexposure prophylaxis against SARS-CoV-2 infection in the United States. It is important that persons who are moderately to severely immunocompromised, those who might have an inadequate immune response to COVID-19 vaccination, and those with contraindications to receipt of COVID-19 vaccines, exercise caution and recognize the need for additional preventive measures. . . . In addition, persons should have a care plan that includes prompt testing at the onset of COVID-19 symptoms and rapid access to antivirals if SARS-CoV-2 infection is detected.
Access the MMWR article in HTML ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Laboratory-Confirmed COVID-19 Case Incidence Rates among Residents in Nursing Homes by Up-to-Date Vaccination Status—United States, October 10, 2022–January 8, 2023” published in MMWR
CDC published Laboratory-Confirmed COVID-19 Case Incidence Rates among Residents in Nursing Homes by Up-to-Date Vaccination Status—United States, October 10, 2022–January 8, 2023 ([link removed]) in the January 27 issue of MMWR ([link removed]). A portion of the summary appears below.
Nursing home residents who were not up to date with recommended COVID-19 vaccines had a 30%–50% higher risk for acquiring SARS-CoV-2 infection compared with residents who were up to date with COVID-19 vaccines.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
Influenza is still active in some areas; keep vaccinating
Keep encouraging influenza vaccination of those not yet protected. Although this influenza season peaked early, it is not possible to rule out a late season resurgence. CDC’s Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), provides a valuable snapshot of influenza activity state by state.
Influenza Surveillance
For week 3, ending January 21, CDC's Weekly U.S. Influenza Surveillance Report, FluView ([link removed]), reports that nationwide, 2.6% of outpatient visits were due to respiratory illness that included fever plus a cough or sore throat (i.e., influenza-like illness [ILI]). This is just above the national baseline of 2.5%. Multiple respiratory viruses are co-circulating; the relative contribution of influenza virus infection to ILI varies by location. So far this season, 91 children have died from influenza-associated causes.
Influenza Vaccination Dashboard
CDC's Weekly Flu Vaccination Dashboard ([link removed]) shows that vaccination coverage for all children age 6 months to age 17 years is similar to the estimate at the same time in January 2022 (50.1% compared with 49.6%) and 3.2 percentage points lower compared with same time in January 2021 (50.1% compared with 53.3%).
CDC recommends everyone age 6 months and older get annual influenza vaccination. “Vaccines.gov” offers VaccineFinder ([link removed]), a service of Boston Children’s Hospital, to help people find influenza and COVID-19 vaccines for any age group. To be listed as a provider by VaccineFinder, see the information at this website ([link removed]).
Related Links
* CDC: Weekly National Flu Vaccination Dashboard ([link removed]) main page
* CDC: FluView ([link removed]) main page
* CDC: Influenza (Flu) ([link removed]) main page
* Immunize.org: free educational materials and patient handouts related to influenza ([link removed])
* Immunize.org: Vaccines: Influenza ([link removed]) main page
* Immunize.org: Ask the Experts: Influenza ([link removed]) main page
* Families Fighting Flu: Flu Resources for Healthcare Professionals ([link removed]) main page
------------------------------------------------------------
CDC revises parts of its General Best Practice Guidelines for Immunization
On January 21, CDC updated the list of errata/updates ([link removed]) for its General Best Practice Guidelines for Immunization ([link removed]). Recent updates include:
Timing and Spacing of Immunobiologics – Unknown or Uncertain Vaccination Status
Page 32, Table 3-2: Fifteen-valent and 20-valent pneumococcal conjugate vaccines (PCV15 and PCV20) were added with an explanatory footnote.
Vaccine Administration
Pages 101, Table 6-1: PCV15 and PCV20 were added.
Storage and Handling of Immunobiologics
Page 120, Table 7-1: PCV15 and PCV20 were added.
Altered Immunocompetence
Page 133: Clarification was added to guidance involving recombinant zoster vaccine (RZV) re-administration to recipients of hematopoietic stem cell transplants. More specificity on the timing of vaccination was added, relative to antiviral timing.
Related Link
* CDC: General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) ([link removed]) (PDF, 198 pages)
Back to top (#Top)
------------------------------------------------------------
Spotlight: Immunize.org resources grouped by age cohorts
In this week's Spotlight, we summarize resources at Immunize.org that focus on specific vaccine products.
Our CDC Schedules ([link removed]) main page provides printable PDFs of the recommended immunization schedules for children and adolescents and for adults.
Our Schedules for Patients ([link removed]) main page contains links to informational sheets on vaccines recommended for people with varying needs based on their age and/or underlying medical conditions.
Within our Handouts: Topic Index ([link removed]) we feature:
* Adult Vaccination ([link removed])
* Adolescent Vaccination ([link removed])
* Parent Handouts ([link removed])
------------------------------------------------------------
Vaccines in the news
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
* Washington Post: FDA Advisers Favor Retiring Original COVID Shot and Using Newer Version ([link removed]) (1/26/23)
* STAT: Live Blog: Tracking the Meeting of the FDA Advisory Panel on COVID Vaccines ([link removed]) (1/26/23)
* U.S. News & World Report: To Sway the Unvaccinated, Latino Teens Deputized as Health Educators ([link removed]) (1/24/23)
* Healio: Children Bore Brunt of ‘Early and Intense’ Flu Season ([link removed]) (1/23/23)
------------------------------------------------------------
Immunize.org Pages and Handouts
------------------------------------------------------------
Immunize.org updates three standing orders templates for adult vaccination—Td/Tdap, Tdap during pregnancy, and meningococcal ACWY
Immunize.org revised three standing orders templates for adult vaccination with added information on the use of the anterolateral thigh muscle as an alternate site for IM injection in adults and QR codes linking to the online versions of the documents. Links and additional changes are shown below.
* Standing Orders for Administering Td/Tdap Vaccine to Adults ([link removed])
* Standing Orders for Administering Tdap Vaccine during Pregnancy ([link removed]): Replaced "pregnant women" with "during pregnancy" in the title
* Standing Orders for Administering Meningococcal ACWY Vaccine to Adults ([link removed]): Added information regarding timing and spacing of additional MenACWY vaccine doses for immunocompromised patients
Related Links
* Immunize.org: Standing Orders Templates for Administering Vaccines ([link removed]) main page
* Immunize.org: Vaccines: Tetanus ([link removed]) main page
* Immunize.org: Vaccines: Diphtheria ([link removed]) main page
* Immunize.org: Vaccines: Pertussis ([link removed]) main page
* Immunize.org: Vaccines: Meningococcal ACWY ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Immunize.org updates handout titled “Leading Medical Organizations Endorse Strong School and Childcare Vaccination Requirements and Elimination of Non-medical Exemptions”
Immunize.org updated its handout titled Leading Medical Organizations Endorse Strong School and Childcare Vaccination Requirements and Elimination of Non-medical Exemptions ([link removed]). This one-page handout for policymakers lists organizations' policies that endorse:
* Childcare and school vaccination requirements
* Elimination of personal belief and religious exemptions
Changes include updated and reaffirmed policy statements from many of the listed medical organizations and the Society for Healthcare Epidemiology of America's policy adopted in 2021. The handout now has a QR code linking to the online version of the document.
Related Links
* Immunize.org: State Laws and Mandates by Vaccine ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Immunize.org updates its patient handout “Rabies: Questions and Answers”
Immunize.org updated its patient handout Rabies: Questions and Answers ([link removed]), organizing questions and answers into sub-categories, incorporating more complete information on pre-exposure prophylaxis, and adding a QR code to link to the online version of the document.
Related Links
* Immunize.org: Handouts: Rabies ([link removed]) main page
* Immunize.org: Handouts for Patients and Staff ([link removed]) main page, where you can sort materials by topic, vaccine, or language
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical listing of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Recap: See updated Immunize.org clinician materials released in December and January
IZ Express regularly provides readers with information about Immunize.org’s new and updated educational materials for healthcare professionals and handouts for patients. All Immunize.org materials are free to distribute.
In case you missed them during recent weeks, updates were made to these helpful materials:
Immunize.org Materials for Clinicians
* Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools ([link removed]) (1/05/23)
* Screening Checklist for Contraindications to Vaccines for Adults ([link removed])
* Vaccines with Diluents: How to Use Them ([link removed])
* Administering Vaccines: Dose, Route, Site, and Needle Size ([link removed])
* Administering Vaccines to Adults: Dose, Route, Site, and Needle Size ([link removed])
* How to Administer Intramuscular and Subcutaneous Vaccine Injections ([link removed])
* How to Administer Intramuscular and Subcutaneous Vaccine Injections to Adults ([link removed])
Immunize.org Web Pages
* Ask the Experts: COVID-19 ([link removed])
* Ask the Experts: Administering Vaccines ([link removed])
* Vaccines: Mpox ([link removed])
Immunize.org Printable Materials for Patients
* After the Shots . . . What to Do if Your Child Has Discomfort ([link removed])
* Reliable Sources of Immunization Information: Where Parents Can Go to Find Answers! ([link removed])
* Protect Yourself from Hepatitis A and Hepatitis B: A Guide for Gay and Bisexual Men ([link removed])
Related Links
* Immunize.org: Handouts ([link removed]) main page to see educational materials sorted by category
* Immunize.org: Ask the Experts ([link removed]) main page to access more than 1,200 questions answered by Immunize.org experts
* Immunize.org: Clinic Tools ([link removed]) main page and its nine subtopics
* Immunize.org: Educational Materials for Patients and Staff ([link removed])—an alphabetical list of more than 230 ready-to-print staff educational materials and patient handouts
------------------------------------------------------------
Vaccine Information Statements
------------------------------------------------------------
Immunize.org continues to expand its translations of new and updated Rabies and Polio Vaccine Information Statements. Be sure to use the latest translations!
Thanks to CDC support, Immunize.org substantially expanded its repository of Vaccination Information Statement (VIS) ([link removed]) translations. Immunize.org posted new and updated VIS translations for HPV, rotavirus, Td, and Tdap vaccines.
All translations are available in print-ready PDF format.
Rabies VIS (view in English ([link removed]))
New! Armenian ([link removed])
New! Dari ([link removed])
New! German ([link removed])
New! Hindi ([link removed])
New! Italian ([link removed])
New! Japanese ([link removed])
New! Khmer (Cambodian) ([link removed])
New! Korean ([link removed])
New! Polish ([link removed])
New! Swahili (Kiswahili) ([link removed])
New! Tagalog ([link removed])
New! Urdu ([link removed])
New! Yiddish ([link removed])
Polio VIS (view in English ([link removed]))
Updated: Armenian ([link removed])
Updated: Farsi ([link removed])
New! German ([link removed])
Updated: Hindi ([link removed])
New! Italian ([link removed])
Updated: Japanese ([link removed])
Updated: Khmer (Cambodian) ([link removed])
Updated: Korean ([link removed])
New! Polish ([link removed])
New! Swahili (Kiswahili) ([link removed])
Updated: Tagalog ([link removed])
New! Urdu ([link removed])
New! Yiddish ([link removed])
Check the version dates of your office copies of newly updated translations. Translations of previous VIS versions should be discarded now that translations of the current versions are available.
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages ([link removed])
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Recap: Use new Vaccine Information Statements and translations released in December and January
In November, with support from CDC, Immunize.org began working with partners to significantly increase the number of Vaccine Information Statement (VIS) translations available. If your facility works with patients whose primary language is not English, please use these translations.
* 29 translations of the Rabies VIS ([link removed])
* 28 translations of the Smallpox/Monkeypox VIS ([link removed])
* 15 translations each of:
+ HPV (Human Papillomavirus) VIS ([link removed])
+ MMRV (Measles, Mumps, Rubella, Varicella) VIS ([link removed])
+ Rotavirus VIS ([link removed])
+ Tdap (Tetanus, Diphtheria, Pertussis) VIS ([link removed])
+ Varicella (Chickenpox) VIS ([link removed])
* 13 translations each of:
+ DTaP (Diphtheria, Tetanus, Pertussis) VIS ([link removed])
+ Hepatitis A VIS ([link removed])
+ Hepatitis B VIS ([link removed])
+ Haemophilus influenzae (Hib) VIS ([link removed])
+ Meningococcal ACWY VIS ([link removed])
+ Meningococcal B VIS ([link removed])
+ Polio VIS ([link removed])
+ Recombinant Zoster (Shingles) VIS ([link removed])
* 6 translations each of:
+ Influenza (Inactivated or Recombinant) VIS ([link removed])
+ Influenza (Live, Intranasal) VIS ([link removed])
+ MMR (Measles, Mumps, Rubella) VIS ([link removed])
+ Td (Tetanus, Diphtheria) VIS ([link removed])
* Dengue VIS ([link removed]) and Ebola VIS ([link removed]) were each translated into Turkish
Related Links
* Immunize.org: Vaccine Information Statement ([link removed]) main page for VISs in 47 languages
* Immunize.org: Dates of Current Vaccine Information Statements ([link removed]) (PDF)
* CDC: What's New with VISs ([link removed]) web page
* CDC: Current VISs ([link removed]) web page
------------------------------------------------------------
Featured Resources
------------------------------------------------------------
Updated 65+ Flu Defense website offers resources for healthcare professionals caring for older adults
Confident recommendations for influenza vaccine from healthcare providers are powerfully persuasive. To assist you in maximizing protection for your patients, Immunize.org, in collaboration with CSL Seqirus, updated the 65+ Flu Defense ([link removed]) website.
Older adults are at increased risk of severe influenza and COVID-19 illness, including hospitalization and death, especially if they are not up to date on these vaccinations. An updated fact sheet on The Importance of Preventing Influenza and COVID-19, ([link removed]) ([link removed]) offers responses to help guide discussions with patients on the importance of preventing influenza and COVID-19.
This helpful site includes information, tools, and tips for communicating with adults age 65 and older about the scope and severity of influenza. Resources include:
* Influenza in Adults 65+: The Facts ([link removed])
* Influenza Vaccination: Questions Patients Aged 65 and Older Frequently Ask Their HCP ([link removed])
* The Importance of Preventing Influenza and COVID-19 ([link removed])
Check out the updated 65+ Flu Defense website at www.influenza-defense.org ([link removed]) to assist your ongoing efforts in protecting this vulnerable population.
------------------------------------------------------------
Explore the www.Give2MenACWY.org website to increase coverage with the MenACWY booster and other adolescent vaccinations
Immunize.org's www.Give2MenACWY.org ([link removed]) website promotes the importance of adolescent vaccination, including the recommended MenACWY vaccine booster dose at age 16. Many teens are behind on vaccines because of the pandemic, so vaccination is more important than ever.
Materials on this colorful website for healthcare professionals incorporate the 2020 ACIP meningococcal vaccine recommendations ([link removed]) and coverage statistics from CDC’s National Immunization Survey–Teen (NIS–Teen). One particularly popular resource on the site is the updated Algorithm for MenACWY Immunization in Adolescents 11 through 18 Years of Age ([link removed]).
The website is divided into five easy-to-access sections:
* Vaccinate Teens ([link removed]) – Teen vaccination schedules and tips for improving vaccination rates
* Give 2 Doses ([link removed]) – Tools to help improve second dose coverage of MenACWY vaccine
* 16-Year-Old Visit ([link removed]) – Resources to help providers and patients remember the important vaccines recommended for 16-year-olds
* Tools for Providers ([link removed]) – Tools to explain meningococcal ACWY vaccine recommendations and improve coverage for all adolescent vaccines
* Resources ([link removed]) – Links to print materials ([link removed]), organizations ([link removed]) involved in adolescent vaccination, personal stories ([link removed]) about the importance of vaccination, and other resources ([link removed]) of interest
The site also categorizes materials ([link removed]) according to whether they are primarily of interest to providers, to adolescents, or to parents.
Visit Give2MenACWY.org ([link removed]) and enjoy browsing (and deploying) its bountiful resources.
Related Links
* Give2MenACWY.org ([link removed]) website
* Algorithm for MenACWY Immunization in Adolescents 11–18 Years of Age ([link removed])
* MenACWY: You're Not Done If You Give Just One: Give 2 Doses to Strengthen Protection ([link removed])
* Recommending MenACWY: What to Say and How to Say It ([link removed])
* Top 10 Ways to Improve Adolescent Immunization Rates ([link removed])
* Developing an Immunization Culture in Your Office ([link removed])
* Know Your Rates: Measuring Immunization Success in Your Practice ([link removed])
* You're 16: We Recommend These Vaccines for You ([link removed])
* Dear Colleague Letter: 16-Year-Old Patients: Make Sure They Receive Their Annual Well Visit and Vaccinations ([link removed]) – signed by six medical societies
* Ask the Experts: Meningococcal ACWY ([link removed])
* CDC: 2020 ACIP Meningococcal Vaccine Recommendations ([link removed])
* CDC: National, Regional, State, and Selected Local Area Vaccination Coverage among Adolescents Aged 13–17 Years — United States, 2020 ([link removed])
* CDC: Adolescent Vaccination Coverage in the U.S. ([link removed])
------------------------------------------------------------
Notable Publications
------------------------------------------------------------
“SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents after Receipt of Bivalent COVID-19 Vaccine—Ohio and Rhode Island, September–November 2022” published in MMWR
CDC published SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents after Receipt of Bivalent COVID-19 Vaccine—Ohio and Rhode Island, September–November 2022 ([link removed]) on January 27 in MMWR ([link removed]). A portion of the summary appears below.
Among nursing home residents in two states, SARS-CoV-2 antibody levels waned within months after vaccination, irrespective of previous SARS-CoV-2 infection, after monovalent booster vaccination. Antibody response broadened after the COVID-19 bivalent booster for vaccinated nursing home residents among those with and without previous infection.
Access the MMWR article in HTML ([link removed]) or PDF ([link removed]).
Related Link
* MMWR's main page ([link removed]) provides access to MMWR Weekly and its companion publications
------------------------------------------------------------
“Persistent COVID-19 Symptoms at 6 Months after Onset and the Role of Vaccination before or after SARS-CoV-2 Infection” published in Infectious Diseases
In the January 18 issue, Infectious Diseases published Persistent COVID-19 Symptoms at 6 Months after Onset and the Role of Vaccination before or after SARS-CoV-2 Infection ([link removed]). The Conclusions and Relevance and the Meaning sections appear below.
In this cohort study, more severe acute illness, a higher Charlson Comorbidity Index score, and being unvaccinated were associated with a higher risk of reporting COVID-19 symptoms lasting 28 days or more. Participants with COVID-19 were more likely to seek medical care for diabetes, pulmonary, neurological, and mental health–related illness for at least 6 months after onset compared with their pre-COVID baseline health care use patterns. . . .
The findings suggest that COVID-19 is associated with increased health care encounters through 6 months after infection; vaccination was associated with lower risk of long-term COVID-19 symptoms.
------------------------------------------------------------
Upcoming Events
------------------------------------------------------------
Virtual: Watch February 22–24 ACIP meeting; agenda is now available
Event: CDC will convene its Advisory Committee on Immunization Practices ([link removed]) (ACIP).
When:
* February 22 and 23, 8:00 a.m.–5:30 p.m. (ET)
* February 24, 8:00 a.m.–1:10 p.m. (ET)
Agenda ([link removed]): mpox, rotavirus, influenza, pneumococcal, meningococcal, polio, respiratory syncytial virus (pediatric/maternal and adult), chikungunya, dengue, varicella, and COVID-19 vaccines
Registration: Not needed. Opportunities for public comment are described at the website.
Related Links
* ACIP main page ([link removed]) for access to webcast, agendas
* ACIP: Meeting Information ([link removed]) for presentation slides, content from previous meetings, and information about future meetings
------------------------------------------------------------
For more upcoming events, visit our Calendar of Events ([link removed]).
Editorial Information
Editor-in-Chief
Kelly L. Moore, MD, MPH
Managing Editor
John D. Grabenstein, RPh, PhD
Associate Editor
Sharon G. Humiston, MD, MPH
Writer/Publication Coordinator
Taryn Chapman, MS
Courtnay Londo, MA
Style and Copy Editor
Marian Deegan, JD
Web Edition Managers
Arkady Shakhnovich
Jermaine Royes
Contributing Writer
Laurel H. Wood, MPA
Technical Reviewer
Kayla Ohlde
About IZ Express
Immunize.org welcomes redistribution of this issue of IZ Express or selected articles. When you do so, please add a note that Immunize.org is the source of the material and provide a link to this issue ([link removed]).
IZ Express is supported in part by Grant No. 1NH23IP922654 from the National Center for Immunization and Respiratory Diseases, CDC. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer ([link removed])
ISSN: 2771-8085
To unsubscribe to this publication, go to: [link removed]
==============================================
Unsubscribe [email protected] from this list:
[link removed]
Message Analysis
- Sender: Immunization Action Coalition
- Political Party: n/a
- Country: United States
- State/Locality: n/a
- Office: n/a
-
Email Providers:
- MailChimp